Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Bicalutamide + LHRH-A vs. flutamide + LHRH-A for metastatic prostate cancer

Oct. 29, 1997

Banyu discloses protein farnesyltransferase inhibitors

Oct. 29, 1997

Biomeasure discloses protein farnesyltranserase inhibitors

Oct. 29, 1997

Antitumor effects of Techniclone's LYM-2 reported

Oct. 29, 1997

Research team identifies effector of morphological changes during apoptosis

Oct. 28, 1997

Oxford BioMedica acquires novel anticancer technology

Oct. 28, 1997

Endorex raises funds for clinical testing of antitumor drugs

Oct. 28, 1997

Preclinical studies on FK-317 presented at cancer meeting

Oct. 28, 1997

DAB-720: a new EGF receptor TK inhibitor from Mitsubishi Chemical

Oct. 28, 1997

Mechanism of action and in vivo antitumor efficacy reported for CS-682

Oct. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...